(603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Operating Data for Q3 2026
Filed with SSE · Stock code 603235 · · 2 pages · Chinese
Summary by 6ix AI
The report includes revenue figures categorized by product, channel, and region, showing a mix of increases and decreases compared to the previous year. The company emphasizes that the data is unaudited and advises investors to be cautious in their decision-making.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
On 6ix: 6ix.com/news/603235jiangxi-tianxin-pharmaceutical-co-ltdannouncement-on-operating-data-for-q3-2026
JiangXi Tianxin Pharmaceutical Co., Ltd. on 6ix
Story so far
Earlier from JiangXi Tianxin Pharmaceutical
- (603235)"JIANGXI TIANXIN PHARMACEUTICAL CO., LTD."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
- Announcement on Operating Data for Q2 2026
- Announcement on Convening the 2026 Semi-annual Performance Briefing
- Announcement on Implementation of Dividend Distribution for 2025
- Announcement on Partial Completion of Canceling Special Accounts for Raised Funds
Follow JiangXi Tianxin Pharmaceutical into a list and get an email when it puts out news.
Follow JiangXi Tianxin Pharmaceutical